It’s time to rethink clinical trials in a post-pandemic world

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Becky Stephens is more than willing to go to great lengths for a miracle. With a diagnosis of stage 4 colon cancer and chemo treatments that weren’t working, she was desperate for hope—and found it in a clinical trial. 

So, the mother of three started making the often, four-hour round-trip trek from Santa Rosa to UCSF Medical Center every two weeks to participate. But the travel was tough. Aside from the cancer treatment leaving her exhausted, the long car trips were wearing on her. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation
Table of Contents

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation

Login